Drug data last refreshed 5d ago
MENTAX-TC is a topical antifungal cream containing butenafine hydrochloride, approved in 2002 for the treatment of tinea pedis (athlete's foot). It is a small-molecule antifungal that disrupts fungal cell membrane integrity through inhibition of sterol synthesis.
With LOE approaching and moderate competitive pressure (30), the brand team is likely in transition mode—expect focus on defensive positioning and generic transition planning rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
SINGLE-APPLICATION TERBINAFINE HYDROCHLORIDE (1%) TOPICAL LIQUID SOLUTION VERSUS A SINGLE-APPLICATION BUTENAFINE HYDROCHLORIDE (1%) TOPICAL LIQUID SOLUTION FOR THE TREATMENT OF TINEA PEDIS
Working on MENTAX-TC offers limited career growth potential given its LOE-approaching status and zero linked job opportunities in the market. Roles are concentrated in defensive commercial and transition management rather than high-visibility growth or innovation initiatives.
Worked on MENTAX-TC at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.